This cohort study uses Netherlands Cancer Registry data to compare the long-term risk of breast cancer among subfertile women treated with ovarian stimulation and in vitro fertilization (IVF) vs non-IVF treatment between 1980 and 1995.
This Medical News feature looks at why an increasing number of women with breast cancer are choosing contralateral prophylactic mastectomy, as well as approaches to improve the decision-making process for women considering their surgical options.
This cluster random clinical trial tested the effects of reversing the order in which mammograms were read by a second radiologist on the rates of breast cancer detection among 46 screening centers in England.
Diagnostic mammography revealed 2 masses in the left breast of a 35-year-old woman. Image-guided core biopsies revealed a poorly differentiated invasive ductal adenocarcinoma. Estrogen receptor was strongly positive in 95% of tumor cells, progesterone receptor was positive in less than 5% of tumor cells, and ERBB2 (HER2) by immunohistochemistry was scored at 1+. How do you interpret the test results?
This randomized clinical trial evaluates the effects of ovarian suppression using the luteinizing hormone–releasing hormone analogue triptorelin on long-term ovarian function, pregnancies, and disease-free survival among premenopausal women receiving adjuvant breast cancer chemotherapy.
A 55-year-old woman presented with a generalized erythematous maculopapular rash after receiving breast cancer chemotherapy. She was afebrile and had no constitutional symptoms; laboratory evaluation revealed pancytopenia, and a computed tomography scan showed no metastasis. What would you do next?
This guideline updates the American Cancer Society breast cancer screening recommendations for women at average risk for breast cancer.
This systematic review reports that among US women at average risk for breast cancer, mammographic screening is associated with reduction in breast cancer mortality, but the magnitude of the benefits and harms of different screening strategies remains uncertain.
This Viewpoint discusses the tension between increased availability of genetic testing and the usefulness of test results for clinical decision making in the context of breast cancer.
This genetic epidemiology study reports that risk of breast and ovarian cancer among women with BRCA1 and BRCA2 mutations varies by mutation type and location.
Elmore and coauthors quantify the magnitude of diagnostic disagreement among pathologists from 8 US clinical practices compared with a consensus panel reference diagnosis and evaluate associated patient and pathologist characteristics.
This observational database study using the Surveillance, Epidemiology, and End Results 18 registries reports that among US women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity.